Meropenem/vaborbactam plus aztreonam for the treatment of New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae infections

J Antimicrob Chemother. 2023 Sep 5;78(9):2377-2379. doi: 10.1093/jac/dkad206.

Authors

Giusy Tiseo¹, Lorenzo Roberto Suardi¹, Alessandro Leonildi², Cesira Giordano², Simona Barnini², Marco Falcone¹

Affiliations

¹ Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
² Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.

PMID: 37392133
DOI: 10.1093/jac/dkad206

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Aztreonam* / pharmacology
Aztreonam* / therapeutic use
Drug Combinations
Humans
Klebsiella Infections* / drug therapy
Klebsiella pneumoniae
Meropenem / therapeutic use
Microbial Sensitivity Tests
beta-Lactamases

Substances

Meropenem
Aztreonam
beta-lactamase NDM-1
vaborbactam
Anti-Bacterial Agents
beta-Lactamases
Drug Combinations